TLR9 and melanoma: With the same technology used for the previously explained GALA modification, Morishita M. et al. modified B16BL6 murine melanoma cell line to attach the Toll-Like Receptor 9 agonist (TLR9) CpG DNA to exosomes (Fig. 6).